Incidence of glaucomatous visual field loss after two decades of follow-up: the Rotterdam Study by Springelkamp, H. (Henriët) et al.
OPHTHALMIC EPIDEMIOLOGY
Incidence of glaucomatous visual field loss after two decades
of follow-up: the Rotterdam Study
Henrie¨t Springelkamp1,2 • Roger C. Wolfs1,2 • Wishal D. Ramdas1,2 •
Albert Hofman1 • Johannes R. Vingerling1,2 • Caroline C. Klaver1,2 •
Nomdo M. Jansonius1,3
Received: 3 November 2016 / Accepted: 3 June 2017
 The Author(s) 2017. This article is an open access publication
Abstract To determine the incidence of glaucomatous
visual field loss (GVFL) two decades after the start of the
Rotterdam Study, and to compare known risk factors for
open-angle glaucoma (OAG) between different clinical
manifestations of OAG. Of 6806 participants aged 55 years
and older from the population-based Rotterdam Study,
3939 underwent visual field testing at baseline and at least
one follow-up round. The ophthalmic examinations inclu-
ded optic disc assessment and measurements of intraocular
pressure (IOP), refractive error, diastolic blood pressure
(DBP), and height and weight. The incidence rate of GVFL
was calculated. Associations with the risk factors age,
gender, baseline IOP, family history, myopia, DBP, and
body-mass index [BMI] were assessed using Cox regres-
sion, with different clinical manifestations of OAG as
outcome measure (glaucomatous optic neuropathy (GON),
GVFL, GVFL and GON, GVFL without GON, and GON
without GVFL). Median follow-up was 11.1 (IQR
6.8–17.2; range 5.0–20.3) years. The incidence rate of
GVFL was 2.9 (95% confidence interval 2.4–3.4) per 1000
person years (140 cases with incident GVFL in one
(n = 113) or both (n = 27) eyes). Baseline IOP and age
were significantly associated with all OAG outcomes (all
p\ 0.001); BMI showed a non-significant protective effect
in all outcomes (p = 0.01 to p = 0.09). Gender, myopia,
and DBP were not associated with any outcome. Our study
provides an estimate of the long-term incidence of GVFL
in a predominantly white population. The development of
GVFL was strongly associated with baseline IOP and age.
Risk factor profiles were similar for the different outcomes.
Keywords Glaucoma  Incidence  Optic nerve  Visual
field  Intraocular pressure
Introduction
Glaucoma is a group of diseases that affect the optic nerve.
Primary open-angle glaucoma (OAG) is one of the most
common forms of glaucoma. It is characterized by loss of
retinal ganglion cells (RGCs) and thinning of the retinal
nerve fiber layer (RNFL). Another hallmark is excavation
of the optic nerve head (ONH), glaucomatous optic neu-
ropathy (GON). These structural changes are visible by
fundoscopy or can be assessed with imaging techniques
like scanning laser ophthalmoscopy, scanning laser
polarimetry, or optical coherence tomography. In general,
loss of RGCs and RNFL leads to visual field defects. This
functional loss can be measured by perimetry. The sur-
prisingly weak association between structural and func-
tional changes in individual patients is one of the major
unsolved issues in glaucoma.
In a general ophthalmology clinical setting, an examina-
tion of the ONH and a measurement of the intraocular pres-
sure (IOP) belong to standard care, whereas perimetry does
not. Perimetry will only be performed in patients with a
suspicious appearance of the ONH or an elevated IOP. This
biases the clinical manifestation of OAG towards high-ten-
sion glaucoma (HTG) and/or pronounced ONH
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abnormalities. The clinical impression that normal tension
glaucoma (NTG) patients have more pronounced ONH
abnormalities than HTG patients (at a given level of visual
field loss) might be the result of this bias, since HTG can be
detected after an IOP measurement in the absence of a sus-
picious ONH appearance. Population-based studies that
perform perimetry in all subjects avoid this bias. This makes
these studies unique for studying the different clinical man-
ifestations of OAG, for example differences in the structure–
function relationship between HTG and NTG. Interestingly,
NTG with an apparently normal ONH appearance, the man-
ifestation of OAG that is very difficult to detect in a clinical
setting, is all but rare in a population-based setting [1, 2].
The aims of our study were (1) to determine the incidence
of GVFL two decades after the start of the Rotterdam Study
and (2) to compare risk factor profiles in various OAG out-
comes: GVFL,GON,GVFLandGON,GVFLwithoutGON,
and GON without GVFL. With this approach we aim to
address the question whether OAG with dominating GVFL
or dominating GON are different entities or not.
Methods
Study population
The Rotterdam Study is a population-based study executed
in Ommoord, a district of Rotterdam, the Netherlands. The
design and background have been published previously [3].
The research described in this paper is based on Rotterdam
Study I (RS-I), which is the original cohort that started in
1990. RS-I included 7983 participants aged 55 years and
older. The ophthalmic part of the RS-I started in 1991 and
comprised 6806 participants [4]. Follow-up rounds were
completed from 1993 to 1995 (RS-I-2; no glaucoma
assessments), 1997 to 1999 (RS-I-3) [2], 2002 to 2004 (RS-I-
4) [1], and 2009 to 2011 (RS-I-5). Ophthalmic baseline and
follow-up examinations included visual field testing, ONH
assessment, and measurements of the intraocular pressure
and refractive error. The Rotterdam Study was approved by
theMedical Ethics Committee of the ErasmusMCand by the
Ministry of Health, Welfare and Sport of the Netherlands,
implementing the ‘‘Wet Bevolkingsonderzoek: ERGO
(Population Studies Act: Rotterdam Study)’’. All partici-
pants provided written informed consent in accordance with
the Declaration of Helsinki to participate in the study and to
obtain information from their treating physicians.
Visual field testing and definition of glaucomatous
visual field loss
All participants underwent visual field testing using the
Humphrey Field Analyzer (HFA; Carl Zeiss Meditec, Jena,
Germany). Details have been published before. In short, the
visual field of both eyes from each participant was screened
with a 52-point supra-threshold test, which tests the 52
points from the Glaucoma Hemifield Test. If a participant
did not respond to a light stimulus (6 dB above a threshold-
related estimate of the hill of vision) in three or more
contiguous points, or four when the defect contained the
blind spot, a second supra-threshold test was performed. If
the second supra-threshold test showed at least partially
(one or more test locations) overlapping abnormalities in
the same Hemifield, Goldmann kinetic perimetry (RS-I-1
and RS-I-3; Haag Streit) or full-threshold HFA (RS-I-4,
RS-I-5) was performed on both eyes. The Goldmann visual
fields were classified according to definitions published
before [5]. The full-threshold HFA tests were classified as
abnormal if at least one of three criteria was met: (1) a
Glaucoma Hemifield Test ‘outside normal limits’, (2) a
minimum of three contiguous points in the pattern devia-
tion probability plot with a sensitivity decreased to
p\ 0.05 of which at least one point to p\ 0.01, or (3) a
Pattern Standard Deviation p\ 0.05. Visual field loss was
considered to be present if it was consecutive and repro-
ducible, that is, the abnormalities had to be present on the
Goldmann or full-threshold test and on both supra-thresh-
old tests. Defects had to be in the same hemifield and at
least one depressed test point had to have exactly the same
location on all fields. Fields had to be reliable, that is, false
positives and false negatives had to be\33% and fixation
losses \20%. Fundus photographs, ophthalmic examina-
tion reports, medical histories, and MRI scans of the brain
were checked for disorders that could explain the visual
field loss. If no other cause could be identified, and no
homonymous defects and artifacts like rim artifacts were
found, the visual field loss was considered GVFL. Dis-
crepancies were resolved by consensus. If the GVFL was
already detected in regular care, additional information was
retrieved from the involved ophthalmologist in order to
exclude angle-closure and secondary glaucoma. Newly
detected cases were invited for a detailed ophthalmic
examination. The current study only included GVFL due to
OAG, including primary OAG, pseudoexfoliation glau-
coma, and pigment dispersion glaucoma.
The pattern of visual field loss was classified using the
Ocular Hypertension Treatment Study classification [6].
This classification describes 17 categories, including alti-
tudinal defect, (partial) arcuate scotoma, and a nasal step.
A recent prototypical (archetypal) analysis showed that
these categories fit well into models of retinal structures
(RNFL trajectories) [7]. Hemifield asymmetry was deter-
mined by comparing, in the full-threshold HFA tests, the
number of abnormal test locations at p\ 0.5% (black
squares) in the total deviation probability plot between the
superior and the inferior hemifield.
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Optic nerve head assessment and definition
of glaucomatous optic neuropathy
During baseline and the first follow-up with glaucoma
assessment (RS-I-3), simultaneous stereo color photos of
the ONH were taken at a fixed angle of 20 degrees and
analyzed with a computerized image analyzer (Topcon
ImageNet System; ImageNet, Topcon Corporation, Tokyo,
Japan). For ImageNet, GON was based on the 97.5th per-
centile of the vertical cup-disc ratio (VCDR). GON was
present if VCDR exceeded 0.69 for small discs (up to
2 mm2), 0.72 for discs 2.0–2.7 mm2, and 0.76 for large
discs ([2.7 mm2) [1]. During the second and third follow-
up rounds (RS-I-4 and RS-I-5, respectively), the Heidel-
berg Retina Tomograph (HRT; Heidelberg Engineering,
Dossenheim, Germany) was used to assess the ONH. The
GON cut-off values for HRT were based on the 97.5th
percentile of the linear cup-disc ratio (LCDR) and defined
as follows: 0.67 for small discs (up to 1.5 mm2), 0.71 for
discs 1.5–2.0 mm2, and 0.76 for large discs ([2.0 mm2)
[8].
Definitions of OAG
Participants without GVFL at baseline who developed
GVFL in at least one eye during follow-up were considered
incident GVFL (iGVFL) cases. Definite OAG was defined
as iGVFL with GON [1]. The presence of GON was
recorded at the last follow-up examination with both reli-
able ONH imaging and visual field testing in participants
without iGVFL, and at the visit where the iGVFL occurred
in participants with iGVFL. Because of the change in ONH
assessment technique during the follow-up, we did not
study incident GON separately.
Intraocular pressure and refraction
IOP was measured with Goldmann applanation tonometry
(Haag-Streit, Bern, Switzerland). For each eye, the median
of three measurements was taken. Refraction was measured
with the RM-A2000 autorefractor (Topcon, Tokyo, Japan).
Statistical analysis
Incidence of glaucomatous visual field loss and definite
open-angle glaucoma
For each participant, we calculated the time between the
baseline visit (RS-I-1) and the last follow-up visit. For
cases with iGVFL, the last follow-up visit was the first visit
with GVFL. For controls, the last follow-up visit was the
last visit with reliable visual field testing. Participants with
GVFL at baseline were excluded, as well as participants
with no reliable visual field testing at baseline or follow-up.
We calculated the incidence rate (IR) and used the IR to
calculate the overall incidence during the entire follow-up.
The IR is calculated as the number of cases with iGVFL
divided by the number of person years (the sum of follow-
up time of all participants). The overall incidence during
the entire follow-up was calculated using the formula 1
ehTiIR; where e is the base of the natural logarithm, hTi
the mean follow-up of all participants, and IR the incidence
rate [9]. The incidence rate and overall incidence during
the entire follow-up of definite OAG was calculated simi-
larly, based on iGVFL cases with GON (see above). We
further calculated the IR of iGVFL in 10-years age cate-
gories. For this analysis we used a dynamic population, i.e.,
participants could contribute person years to subsequent
age categories [10]. In this analysis we also stratified for
gender.
Risk factor analysis and clinical manifestations of OAG
The following baseline risk factors were analyzed: age,
gender, IOP, IOP treatment, family history for glaucoma,
myopia, diastolic blood pressure (DBP), and body-mass
index (BMI). For IOP, we took the highest value of the
medians of both eyes (see above) at baseline. IOP treat-
ment was defined as IOP lowering surgery or laser treat-
ment before baseline or the use of IOP lowering medication
at baseline. Medication use was based on a fully automated
pharmacy database recording including the ATC code
(S01E for IOP lowering medication). Surgery and laser
treatment were based on interview data with the partici-
pant. Family history was considered positive if the partic-
ipant reported glaucoma in parents, siblings, or offspring
during the interview. Spherical equivalent refraction (SE)
was calculated as the spherical refractive error plus half of
the cylinder. It was stratified in three categories: high
myopia, defined as a SE of -4 D or more myopic; low
myopia, defined as a SE between -3.99 and -0.01 D; and
no myopia, defined as a SE of 0 D and above. For SE, we
used the eye with GVFL in case of unilateral GVFL, and a
random eye in case of bilateral GVFL and participants
without GVFL. The assessment of DBP has been described
before [11]. BMI was calculated as mass (in kilograms)
divided by the square of height (in meters). Height and
weight were measured with indoor clothing and no shoes.
In case of missing values for the risk factors, we imputed
the missing value to the mean since missing values were
present in less than 5% of the participants. In case of cat-
aract extraction in both eyes before baseline, the SE was
imputed to the mean; in case of cataract extraction in one
eye, the SE of the other eye was taken.
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Risk factor analyses were performed using Cox pro-
portional hazards models, with five different outcome
measures: (1) iGVFL, (2) GON, (3) iGVFL and GON
(definite OAG), (4) iGVFL without GON, and (5) GON
without iGVFL. For each analysis, controls were partici-
pants without iGVFL and without GON. For this analysis,
the last follow-up round with both reliable visual field
testing and ONH data was used. Similar to iGVFL (see
above, Definitions of OAG), GON was defined as the
presence of GON in at least one eye. A Bonferroni-cor-
rected p value of 0.01 (0.05/5 analyses) was considered as
statistically significant.
In a final comparison, a one-way ANOVA was con-
ducted to compare the mean IOP between participants with
GVFL and GON (definitive OAG), GVFL without GON,
GON without GVFL, and controls; since there was no
homogeneity of variance, the Games-Howell post hoc test
was used to compare all groups to each other. A p value of
0.05 was considered as statistically significant. All analyses
were performed using IBM SPSS Statistics Release 20.0.0
(IBM Corp., Armonk, NY).
Results
After exclusion of participants with GVFL at baseline and
participants without visual field testing at follow-up, 3939
participants were eligible for the study (see Fig. 1). Table 1
presents the baseline characteristics with univariable
comparisons. Of the 3939 participants, 140 developed
GVFL during one of the follow-up rounds. The median
follow-up was 11.1 (IQR 6.8–17.2; range 5.0–20.3) years,
the mean follow-up 12.1 years, and the total follow-up
47,710 person-years. The incidence rate was 2.9 (95% CI
2.4–3.4) per 1000 person years; the 12-years incidence was
3.5 (2.9–4.0)%. For definite OAG, the incidence rate per
1000 person-years and 12-years incidence were 1.0
(0.7–1.3) and 1.2 (0.9–1.5)%, respectively. Table 2 pre-
sents age- and gender-specific incidence rates of GVFL.
The incidence rate increased from 0.8 at age 55–64 years
to 12.7 per 1000 person years at age 85 and above.
Of the 140 iGVFL cases, 27 (19.3%) had bilateral
iGVFL at the time of diagnosis, 52 (37.1%) had iGVFL in
only the right eye, and 61 (43.6%) had iGVFL in only the
left eye (p = 0.42). Of these 113 unilateral cases, 8 cases
developed GVFL in the second eye during a later follow-up
round. Of all the iGVFL cases, 89 were diagnosed with the
full threshold HFA (RS-I-4 and RS-I-5) of which 17 had
bilateral iGVFL. Seven of these 106 (89 ? 17) eyes (six
cases) showed an altitudinal defect (all in the upper
hemifield); 30 eyes showed an arcuate scotoma in one
hemifield (20 upper hemifield, 10 lower hemifield), and 50
eyes showed an arcuate scotoma in both hemifields. Fifteen
eyes showed a partial arcuate scotoma (8 upper hemifield,
4 lower hemifield, and 3 in both hemifields); 4 eyes showed
a nasal step (1 upper hemifield, 2 lower hemifield, 1 both
hemifields). Overall, 36 eyes had a scotoma in the superior
hemifield only, 16 in the inferior hemifield only
(p = 0.01), and 54 in both hemifields. In 56 of the 106 eyes
(52.8%) the upper hemifield was more severely affected
than the lower hemifield (not significantly different from
50%; p = 0.35). This indicates that, if scotomata are pre-
sent in both hemifields, the loss is more pronounced infe-
riorly than superiorly. Indeed, in the 54 eyes with a
scotoma in both hemifields, on average 11.9 test locations
were affected in the upper hemifield and 14.3 in the inferior
hemifield (at p\ 0.5% (black squares) in the total devia-
tion probability plot).
Of the 140 cases with iGVFL, 24 participants had GON
at baseline (as assessed with ImageNet) and 48 had GON at
follow-up (as assessed with HRT). Another 251 partici-
pants had GON at follow-up but no iGVFL (Fig. 2). Of the
participants without GON at the time that iGVFL was
diagnosed, 10 developed GON in a next follow-up round.
Fig. 1 Flow diagram which shows the number of participants with
reliable visual field testing in the different follow-up rounds. FU
follow-up, GVFL glaucomatous visual field loss, RS-I Rotterdam
Study I, RS-I-1 baseline examinations, RS-I-3 first follow-up round,
RS-I-4 second follow-up round, RS-I-5 third follow-up round
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Figure 3 shows the VCDR (A; RS-I-3) and LCDR (B; RS-
I-4 and RS-I-5) distributions of cases with iGVFL and
controls. Although two-third of the cases with iGVFL did
not have GON formally, the distributions of the iGVFL
cases were clearly shifted towards higher VCDR/LCDR
values, when compared to the controls (participants with-
out iGVFL).
The differences in risk factors between participants with
iGVFL and/or GON are shown in Table 3. IOP and age
were significant risk factors for all outcomes. A positive
family history was associated with iGVFL, GON, and
definite OAG. Gender, myopia, and DBP were not signif-
icantly associated with any of the outcomes; BMI appeared
to be associated with various outcomes, but only for GON
at the Bonferroni-corrected p = 0.01.
The mean baseline IOP in participants with definite
OAG was 18.4, in iGVFL without GON 16.3, in GON
without iGVFL 15.8, and in the controls 15.0 mmHg. Post
hoc comparisons using the Games-Howell test indicated
that the mean IOP was significantly different between the
controls and all other groups. Furthermore, the mean IOP
was significantly different between definite OAG and
Table 1 Baseline demographic
and clinical characteristics of
participants with and without
iGVFL, presented as
mean ± SD or percentages
No GVFL (n = 3799) iGVFL (n = 140) p value
Age (years) 65.7 ± 6.8 67.2 ± 7.0 0.01
Gender (female) 58.6% 54.3% 0.32
IOP (mmHg) 15.0 ± 3.1 17.0 ± 4.4 \0.001
IOP Rx 1.6% 10.0% \0.001
FH 8.0% 17.9% \0.001
Myopia 0.56
Low myopia 20.7% 19.3%
High myopia 5.0% 7.1%
DBP (mmHg) 73.6 ± 10.8 72.8 ± 12.0 0.36
BMI (kg/m2) 26.3 ± 3.5 25.7 ± 3.1 0.03
BMI body-mass index, DBP diastolic blood pressure, FH positive family history for glaucoma, iGVFL
incident glaucomatous visual field loss, IOP intraocular pressure, IOP Rx intraocular pressure lowering
treatment
Table 2 Incidence rates of glaucomatous visual field loss as a function of age and gender
Age group (years) Number of cases Person years at risk IR per 1000 person years (95% CI) 12-years risk (95% CI)
Male
55–64 2 3950 0.5 (0.0–1.2) 0.6 (-0.2–1.4)%
65–74 23 10,180 2.3 (1.3–3.2) 2.7 (1.6–3.7)%
75–84 32 4951 6.5 (4.2–8.7) 7.5 (4.9–9.9)%
85? 7 478 14.6 (3.8–25.5) 16.1 (4.5–26.3)%
Overall 64 19,560 3.3 (2.5–4.1) 3.9 (2.9–4.8)%
Female
55–64 5 5331 0.9 (0.1–1.8) 1.1 (0.1–2.1)%
65–74 17 13,615 1.2 (0.7–1.8) 1.5 (0.8–2.2)%
75–84 40 8030 5.0 (3.4–6.5) 5.8 (4.0–7.5)%
85? 14 1174 11.9 (5.7–18.2) 13.3 (6.6–19.6)%
Overall 76 28,150 2.7 (2.1–3.3) 3.2 (2.5–3.9)%
Total
55–64 7 9281 0.8 (0.2–1.3) 0.9 (0.2–1.6)%
65–74 40 23,795 1.7 (1.2–2.2) 2.0 (1.4–2.6)%
75–84 72 12,982 5.5 (4.3–6.8) 6.4 (5.0–7.9)%
85? 21 1652 12.7 (7.3–18.2) 14.1 (8.4–19.6)%
Overall 140 47,710 2.9 (2.4–3.4) 3.5 (2.9–4.0)%
CI confidence interval, IR incidence rate
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participants with GON without iGVFL (p = 0.014). There
was no significant difference in IOP between definite OAG
and iGVFL without GON (p = 0.09) and iGVFL without
GON and GON without iGVFL (p = 0.67).
Discussion
In this study, the 12-years incidences of GVFL and definite
OAG were 3.5 and 1.2%, respectively, and the corre-
sponding incidence rates 2.9 and 1.0 per 1000 person years.
The 12-years incidence of GVFL increased from 0.8 to
12.7% in the age range studied. Unilateral GVFL occurred
as often in the right eye as in the left eye; if only one
hemifield was affected, GVFL was more often present in
the superior hemifield than in the inferior hemifield.
However, the majority of eyes had GVFL in both hemi-
fields and, overall, the glaucomatous damage did not differ
between the hemifields. About one-third of the cases with
iGVFL had GON. Our data do not support the hypothesis
that OAG with dominating GVFL or dominating GON are
different entities, as depicted by the finding that the various
clinical manifestations of OAG did not differ noticeably in
their associations with the established OAG risk factors
studied.
The incidence rate of 2.9 per 1000 person years was
similar to the incidence rate that was found previously in
the Rotterdam Study after 10 years of follow-up [1]. In a
population-based study in Italy, Cedrone et al. [12] found a
12-years incidence of OAG of 3.8% (95% CI 2.3–6.2),
quite similar to our 3.5%. Their definition of OAG was
GVFL plus IOP C 21 mmHg or VCDR C 0.5 or VCDR
asymmetry C 0.2. Hence, their incidence of GVFL without
other criteria would probably be higher. On the other hand,
they only performed visual field testing in suspect glau-
coma (IOP C 21 mmHg or VCDR C 0.5 or VCDR
asymmetry C 0.2) and at random in 50% of the other
individuals. In this way they will have missed some iGVFL
cases, being the cases without elevated IOP and without a
clearly excavated ONH.
In the study from Cedrone et al. [12], 53% of the inci-
dent OAG cases had unilateral visual field loss. Data
concerning the occurrence in right or left eyes was not
provided. A ratio of 1:1 for uni- and bilateral OAG was
also found in the Blue Mountains Eye Study [13]. We
found a greater percentage (81%) of unilateral cases than
these studies. This difference could be explained by the
fact that we examined our individuals on regular time
Fig. 2 Number of participants with incident glaucomatous visual
field loss (iGVFL), glaucomatous optic neuropathy (GON), or both.
The presence of GON was recorded at the last follow-up examination
with both reliable ONH imaging and visual field testing in partici-
pants without iGVFL, and at the visit where the iGVFL occurred in
participants with iGVFL
Fig. 3 Distribution of vertical cup-disc ratio (a) and linear cup-disc
ratio (b) in cases with incident glaucomatous visual field loss
(iGVFL; in black pattern) and controls without GVFL (in white)
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intervals and thus detected the GVFL in an earlier stage of
the disease. The time between the two examinations in the
study from Cedrone et al. was 12 years, while the Blue
Mountains Eye Study described also prevalent cases. In the
Blue Mountains Eye Study, 34.2% of 152 eyes with GVFL
had defects in only the upper hemifield, 40.1% in only the
lower hemifield (p = 0.13), and 25.7% had defects in both
hemifields. This absence of a clear hemifield preference
agrees with our study: we found—in eyes with only one
affected hemifield—a predominance of superiorly over
inferiorly located scotomata, but if both hemifields were
affected, the loss was predominantly located inferiorly.
The clinical implication of this finding is that patients with
glaucomatous loss in the inferior hemifield are more likely
to develop loss in the intact hemifield, compared to
patients with glaucomatous loss in the superior hemifield.
It has been postulated that NTG differs from HTG in
optic nerve head appearance. Caprioli et al. [14] found
thinner optic disc rim in NTG patients (n = 34) compared
to HTG patients (n = 41), especially in the inferior and
inferotemporal area. Iester et al. [15] compared HRT
parameters between HTG patients (n = 132) and NTG
patients (n = 50) and found no statistically significant
differences in any of the parameters. This is in line with the
results of our unbiased study (as argued in the Introduction
section, NTG might bias towards more pronounced ONH
abnormalities in a clinical setting). We were not able to
locate studies addressing asymmetry in left/right eye and/
or inferior/superior hemifield occurrence of GVFL.
We found no association between myopia and any of the
OAG outcomes. A meta-analysis showed that myopia was
associated with glaucoma (odds ratio of 1.9) [16]. Previ-
ously, we also found an association between high myopia
and OAG in the Rotterdam Study (HR 2.3 [1.2–4.5],
p = 0.01) [1]. However, of the 32 participants who
developed GVFL during the latest follow-up round only
one had high myopia and therefore the effect of the asso-
ciation disappeared. Our finding suggests that (high)
myopia may mainly play a role in the development of
OAG at a younger age. After all, the mean age of the
participants at the latest follow-up round (RS-I-5) was
79.5 years (to be compared to 66 years at baseline). This is
supported by a recent study in which participants with high
myopia developed OAG earlier than others [17]. A similar
phenomenon occurred for gender. We previously identified
male gender as a risk factor for glaucoma (HR 1.62
[1.10–2.38], p = 0.015) [1]. The current study found a
higher IR among males but yielded no significant associ-
ations for gender in the risk factor analysis, apparently
related to an excess of females (27) amongst the 32 most
recently diagnosed iGVFL cases (72%). This suggests that
males tend to develop OAG at an earlier age. However, the
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wide confidence intervals in the individual age and gender
categories do not permit firm conclusions.
We found a nominally significant association between
BMI and GVFL (p = 0.02) and BMI and GON (p = 0.01),
which were not significant after correction for multiple
testing. The associations between BMI and the other out-
comes were not significant. However, the hazard ratios
were all in the same—protective—direction (0.92–0.96).
Other studies also found a protective effect of BMI on
OAG [18–22]. Furthermore, previous studies found that a
higher BMI was associated with small cup-disc ratios or
cup areas [23–25], which is in line with our finding that a
higher BMI is protective for GON.
In our study, DBP was not associated with OAG. A
recent meta-analysis, which included 27 studies that
investigated the relationship between blood pressure and
glaucoma, found a pooled relative risk of 1.16 (95% CI
1.05–1.28) for the effect of hypertension (not separately
studied for systolic blood pressure and DBP) on OAG [26].
However, they showed some heterogeneity across studies
(I2 34.5%; 18 studies reported a positive association and 9
studies reported an inverse or no association) and the effect
was only significant in cross-sectional studies; the pooled
relative risk of two longitudinal studies was 1.05
(0.69–1.59). Clearly, the power was limited here, but—
generally speaking —longitudinal studies are more infor-
mative concerning a causal relationship between a risk
factor and a disease. Our results, together with the previous
results from the two longitudinal studies, suggest that there
is no clear association between blood pressure and OAG.
Studying blood pressure as a linear variable implies the risk
of overlooking non-linear associations, for example an
increased risk for those with a very low or a very high
blood pressure. In our study, entering DBP in quartiles did
not reveal any association either (data not shown), sug-
gesting the absence of a clear nonlinear relationship
between OAG and DBP.
A strong point of our study is that all participants
underwent visual field testing, regardless of ONH abnor-
malities or IOP measurements. We showed that two-third
of the iGVFL cases had no ONH abnormalities exceeding
the 97.5th percentile. Studies who performed only visual
field testing in subjects with suspicious ONH findings may
thus miss many OAG cases. A limitation of the study is the
relatively low number of cases, which is inherent to the low
incidence of OAG in the general population but hampers
detailed risk factor analyses.
In conclusion, we found a 12-years incidence of 3.5%
for GVFL. Risk factor profiles were similar for the dif-
ferent clinical manifestations of OAG. We confirmed the
associations between OAG and age, IOP, and family his-
tory. We found no association for either gender or myopia,
and hypothesized that these factors may particularly be
related to OAG with a younger age of onset.
Funding Stichting Lijf en Leven, Krimpen aan de Lek; MD Fonds,
Utrecht; Rotterdamse Vereniging Blindenbelangen, Rotterdam;
Stichting Oogfonds Nederland, Utrecht; Blindenpenning, Amsterdam;
Blindenhulp, The Hague; Algemene Nederlandse Vereniging ter
Voorkoming van Blindheid (ANVVB), Doorn; Landelijke Stichting
voor Blinden en Slechtzienden, Utrecht; Swart van Essen, Rotterdam;
Stichting Winckel-Sweep, Utrecht; Henkes Stichting, Rotterdam;
Lame´ris Ootech BV, Nieuwegein; Medical Workshop, de Meern;
Topcon Europe BV, Capelle aan de IJssel, all in the Netherlands, and
Heidelberg Engineering, Dossenheim, Germany. Henrie¨t Spring-
elkamp is supported by the NWO Graduate Programme 2010 BOO
(022.002.023). The sponsor or funding organization had no role in the
design or conduct of this research.
Compliance with ethical standards
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, De Jong
PT, Vingerling JR, et al. Incidence of glaucomatous visual field
loss: a ten-year follow-up from the Rotterdam Study. Ophthal-
mology. 2010;117(9):1705–12. doi:10.1016/j.ophtha.2010.01.
034.
2. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de
Jong PT. Incidence of open-angle glaucoma in a general elderly
population: the Rotterdam Study. Ophthalmology.
2005;112(9):1487–93. doi:10.1016/j.ophtha.2005.04.018.
3. Hofman A, Brusselle GG, Darwish Murad S, van Duijn CM,
Franco OH, Goedegebure A, et al. The Rotterdam Study: 2016
objectives and design update. Eur J Epidemiol.
2015;30(8):661–708. doi:10.1007/s10654-015-0082-x.
4. Wolfs RC, Borger PH, Ramrattan RS, Klaver CC, Hulsman CA,
Hofman A, et al. Changing views on open-angle glaucoma:
definitions and prevalences—the Rotterdam Study. Invest Oph-
thalmol Vis Sci. 2000;41(11):3309–21.
5. Skenduli-Bala E, de Voogd S, Wolfs RC, van Leeuwen R, Ikram
MK, Jonas JB, et al. Causes of incident visual field loss in a
general elderly population: the Rotterdam Study. Arch Ophthal-
mol. 2005;123(2):233–8. doi:10.1001/archopht.123.2.233.
6. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann
SE, Kass MA, et al. Classification of visual field abnormalities in
the ocular hypertension treatment study. Arch Ophthalmol.
2003;121(5):643–50. doi:10.1001/archopht.121.5.643.
7. Elze T, Pasquale LR, Shen LQ, Chen TC, Wiggs JL, Bex PJ.
Patterns of functional vision loss in glaucoma determined with
archetypal analysis. J R Soc Interface. 2015. doi:10.1098/rsif.
2014.1118.
8. Ramdas WD, Wolfs RC, Hofman A, de Jong PT, Vingerling JR,
Jansonius NM. Heidelberg Retina Tomograph (HRT3) in popu-
lation-based epidemiology: normative values and criteria for
H. Springelkamp et al.
123
glaucomatous optic neuropathy. Ophthalmic Epidemiol.
2011;18(5):198–210. doi:10.3109/09286586.2011.602504.
9. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed.
Philadelphia: Lippincott-Raven; 1998.
10. Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler
MM. Trends in stroke incidence rates and stroke risk factors in
Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol.
2012;27(4):287–95. doi:10.1007/s10654-012-9673-y.
11. Ramdas WD, Wolfs RC, Hofman A, de Jong PT, Vingerling JR,
Jansonius NM. Ocular perfusion pressure and the incidence of
glaucoma: real effect or artifact? The Rotterdam Study. Invest
Ophthalmol Vis Sci. 2011;52(9):6875–81. doi:10.1167/iovs.11-
7376.
12. Cedrone C, Mancino R, Ricci F, Cerulli A, Culasso F, Nucci C.
The 12-year incidence of glaucoma and glaucoma-related visual
field loss in Italy: the Ponza eye study. J Glaucoma.
2012;21(1):1–6. doi:10.1097/IJG.0b013e3182027796.
13. Lee AJ, Wang JJ, Rochtchina E, Healey P, Chia EM, Mitchell P.
Patterns of glaucomatous visual field defects in an older popu-
lation: the Blue Mountains Eye Study. Clin Exp Ophthalmol.
2003;31(4):331–5.
14. Caprioli J, Spaeth GL. Comparison of the optic nerve head in
high- and low-tension glaucoma. Arch Ophthalmol. 1985;103(8):
1145–9.
15. Iester M, Mikelberg FS. Optic nerve head morphologic charac-
teristics in high-tension and normal-tension glaucoma. Arch
Ophthalmol. 1999;117(8):1010–3.
16. Marcus MW, de Vries MM, Junoy Montolio FG, Jansonius NM.
Myopia as a risk factor for open-angle glaucoma: a systematic
review and meta-analysis. Ophthalmology. 2011;118(10):
1989–94. doi:10.1016/j.ophtha.2011.03.012.
17. Shim SH, Sung KR, Kim JM, Kim HT, Jeong J, Kim CY, et al.
The prevalence of open-angle glaucoma by age in myopia: the
Korea National Health and nutrition examination survey. Curr
Eye Res. 2016;. doi:10.3109/02713683.2016.1151053.
18. Charlson ES, Sankar PS, Miller-Ellis E, Regina M, Fertig R,
Salinas J, et al. The primary open-angle african american glau-
coma genetics study: baseline demographics. Ophthalmology.
2015;122(4):711–20. doi:10.1016/j.ophtha.2014.11.015.
19. Gasser P, Stumpfig D, Schotzau A, Ackermann-Liebrich U,
Flammer J. Body mass index in glaucoma. J Glaucoma.
1999;8(1):8–11.
20. Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk
factors for open-angle glaucoma: the Barbados Eye Study. Arch
Ophthalmol. 1995;113(7):918–24.
21. Pasquale LR, Willett WC, Rosner BA, Kang JH. Anthropometric
measures and their relation to incident primary open-angle
glaucoma. Ophthalmology. 2010;117(8):1521–9. doi:10.1016/j.
ophtha.2009.12.017.
22. Wu SY, Leske MC. Associations with intraocular pressure in the
Barbados Eye Study. Arch Ophthalmol. 1997;115(12):1572–6.
23. Khawaja AP, Chan MP, Broadway DC, Garway-Heath DF,
Luben R, Yip JL, et al. Laser scanning tomography in the EPIC-
Norfolk Eye Study: principal components and associations. Invest
Ophthalmol Vis Sci. 2013;54(10):6638–45. doi:10.1167/iovs.13-
12490.
24. Xu L, Wang YX, Wang S, Jonas JB. Neuroretinal rim area and
body mass index. PLoS ONE. 2012;7(1):e30104. doi:10.1371/
journal.pone.0030104.
25. Zheng Y, Cheung CY, Wong TY, Mitchell P, Aung T. Influence
of height, weight, and body mass index on optic disc parameters.
Invest Ophthalmol Vis Sci. 2010;51(6):2998–3002. doi:10.1167/
iovs.09-4470.
26. Zhao D, Cho J, Kim MH, Guallar E. The association of blood
pressure and primary open-angle glaucoma: a meta-analysis. Am J
Ophthalmol. 2014;158(3):615–27. doi:10.1016/j.ajo.2014.05.029.
Incidence of glaucomatous visual field loss after two decades of follow-up: the Rotterdam Study
123
